Cipla arm's oral liquid dosage, nasal product unit acquired by Rubicon Research

Published On 2021-07-11 05:30 GMT   |   Update On 2021-07-11 05:31 GMT
Advertisement

New Delhi: Specialty pharma firm Rubicon Research on Friday said it has acquired Meditab Specialities'' oral liquid dosage and nasal product manufacturing facility at Satara in Maharashtra.

Meditab Specialities is a wholly-owned subsidiary of Cipla.

Without disclosing the deal size, Rubicon Research said the Satara facility is cGMP compliant and MHRA (UK)-inspected production site.

The facility enables a strong and diverse pipeline of oral liquids for Rubicon Research, it said in a statement.

Advertisement

The company will seek additional regulatory approvals for the Satara site, including from the United States Food and Drug Administration (USFDA), it added.

Read also: MSD in talks with 5 Indian drugmakers for clinical trial of COVID drug Molnupiravir

"The acquisition of an outstanding oral liquid and nasal inhalers manufacturing facility advances our plan to offer a wider portfolio to our customers," Rubicon Research CEO Parag Sancheti said.

These capabilities combined with Rubicon''s research and development expertise strengthens the company''s ability to offer best-in-class drug products across dosage forms, he added

Read also: Cipla gets DCGI nod to import Moderna COVID vaccine



Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News